BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38331878)

  • 21. Nifuroxazide Activates the Parthanatos to Overcome TMPRSS2:ERG Fusion-Positive Prostate Cancer.
    Li C; Zhang J; Wu Q; Kumar A; Pan G; Kelvin DJ
    Mol Cancer Ther; 2023 Mar; 22(3):306-316. PubMed ID: 36622760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.
    Mosquera JM; Mehra R; Regan MM; Perner S; Genega EM; Bueti G; Shah RB; Gaston S; Tomlins SA; Wei JT; Kearney MC; Johnson LA; Tang JM; Chinnaiyan AM; Rubin MA; Sanda MG
    Clin Cancer Res; 2009 Jul; 15(14):4706-11. PubMed ID: 19584163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aspirin and NSAID use in association with molecular subtypes of prostate cancer defined by TMPRSS2:ERG fusion status.
    Wright JL; Chéry L; Holt S; Lin DW; Luedeke M; Rinckleb AE; Maier C; Stanford JL
    Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):53-6. PubMed ID: 26503111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intratumoral androgen levels are linked to TMPRSS2-ERG fusion in prostate cancer.
    Knuuttila M; Mehmood A; Mäki-Jouppila J; Ryberg H; Taimen P; Knaapila J; Ettala O; Boström PJ; Ohlsson C; Venäläinen MS; Laiho A; Elo LL; Sipilä P; Mäkelä SI; Poutanen M
    Endocr Relat Cancer; 2018 Sep; 25(9):807-819. PubMed ID: 29773553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.
    Setlur SR; Mertz KD; Hoshida Y; Demichelis F; Lupien M; Perner S; Sboner A; Pawitan Y; Andrén O; Johnson LA; Tang J; Adami HO; Calza S; Chinnaiyan AM; Rhodes D; Tomlins S; Fall K; Mucci LA; Kantoff PW; Stampfer MJ; Andersson SO; Varenhorst E; Johansson JE; Brown M; Golub TR; Rubin MA
    J Natl Cancer Inst; 2008 Jun; 100(11):815-25. PubMed ID: 18505969
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer.
    Todorova K; Metodiev MV; Metodieva G; Mincheff M; Fernández N; Hayrabedyan S
    Horm Cancer; 2017 Feb; 8(1):28-48. PubMed ID: 28050800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DNA Promoter Methylation and ERG Regulate the Expression of CD24 in Prostate Cancer.
    Tolkach Y; Zarbl R; Bauer S; Ritter M; Ellinger J; Hauser S; Hüser L; Klauck SM; Altevogt P; Sültmann H; Dietrich D; Kristiansen G
    Am J Pathol; 2021 Apr; 191(4):618-630. PubMed ID: 33485866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative analysis of ERG expression and its splice isoforms in formalin-fixed, paraffin-embedded prostate cancer samples: association with seminal vesicle invasion and biochemical recurrence.
    Hagen RM; Adamo P; Karamat S; Oxley J; Aning JJ; Gillatt D; Persad R; Ladomery MR; Rhodes A
    Am J Clin Pathol; 2014 Oct; 142(4):533-40. PubMed ID: 25239421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delineation of TMPRSS2-ERG splice variants in prostate cancer.
    Hu Y; Dobi A; Sreenath T; Cook C; Tadase AY; Ravindranath L; Cullen J; Furusato B; Chen Y; Thangapazham RL; Mohamed A; Sun C; Sesterhenn IA; McLeod DG; Petrovics G; Srivastava S
    Clin Cancer Res; 2008 Aug; 14(15):4719-25. PubMed ID: 18676740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High throughput differential identification of TMPRSS2-ERG fusion genes in prostate cancer patient urine.
    Lee H; Lee D; Park JH; Song SH; Jeong IG; Kim CS; Searson PC; Lee KH
    Biomaterials; 2017 Aug; 135():23-29. PubMed ID: 28478327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions.
    Stopsack KH; Su XA; Vaselkiv JB; Graff RE; Ebot EM; Pettersson A; Lis RT; Fiorentino M; Loda M; Penney KL; Lotan TL; Mucci LA
    Mol Cancer Res; 2023 Jan; 21(1):14-23. PubMed ID: 36125519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer.
    Qu X; Randhawa G; Friedman C; O'Hara-Larrivee S; Kroeger K; Dumpit R; True L; Vakar-Lopez F; Porter C; Vessella R; Nelson P; Fang M
    Cancer Genet; 2013; 206(1-2):1-11. PubMed ID: 23352841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EZH2-induced lysine K362 methylation enhances TMPRSS2-ERG oncogenic activity in prostate cancer.
    Zoma M; Curti L; Shinde D; Albino D; Mitra A; Sgrignani J; Mapelli SN; Sandrini G; Civenni G; Merulla J; Chiorino G; Kunderfranco P; Cacciatore A; Kokanovic A; Rinaldi A; Cavalli A; Catapano CV; Carbone GM
    Nat Commun; 2021 Jul; 12(1):4147. PubMed ID: 34230470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retention of Interstitial Genes between
    Murphy SJ; Kosari F; Karnes RJ; Nasir A; Johnson SH; Gaitatzes AG; Smadbeck JB; Rangel LJ; Vasmatzis G; Cheville JC
    Cancer Res; 2017 Nov; 77(22):6157-6167. PubMed ID: 29127096
    [No Abstract]   [Full Text] [Related]  

  • 35. Transcriptomic profiling and genomic rearrangement landscape of Nigerian prostate cancer.
    Mavura Y; Song H; Xie J; Tamayo P; Mohammed A; Lawal AT; Bello A; Ibrahim S; Faruk M; Huang FW
    Prostate; 2023 Apr; 83(5):395-402. PubMed ID: 36598071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis.
    Sandoval GJ; Pulice JL; Pakula H; Schenone M; Takeda DY; Pop M; Boulay G; Williamson KE; McBride MJ; Pan J; St Pierre R; Hartman E; Garraway LA; Carr SA; Rivera MN; Li Z; Ronco L; Hahn WC; Kadoch C
    Mol Cell; 2018 Aug; 71(4):554-566.e7. PubMed ID: 30078722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infiltration of Prostate Cancer by CD204+ and CD3+ Cells Correlates with ERG Expression and TMPRSS2-ERG Gene Fusion.
    Burdova A; Rulisek P; Bouchal J; Král M; Student V; Kolar Z
    Klin Onkol; 2018; 31(6):421-428. PubMed ID: 30545222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amplification-Free Detection of Gene Fusions in Prostate Cancer Urinary Samples Using mRNA-Gold Affinity Interactions.
    Koo KM; Carrascosa LG; Shiddiky MJ; Trau M
    Anal Chem; 2016 Jul; 88(13):6781-8. PubMed ID: 27299694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene fusion characterisation of rare aggressive prostate cancer variants-adenosquamous carcinoma, pleomorphic giant-cell carcinoma, and sarcomatoid carcinoma: an analysis of 19 cases.
    Alhamar M; Tudor Vladislav I; Smith SC; Gao Y; Cheng L; Favazza LA; Alani AM; Ittmann MM; Riddle ND; Whiteley LJ; Gupta NS; Carskadon S; Gomez-Gelvez JC; Chitale DA; Palanisamy N; Hes O; Trpkov K; Williamson SR
    Histopathology; 2020 Dec; 77(6):890-899. PubMed ID: 32639612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer.
    Attard G; Clark J; Ambroisine L; Fisher G; Kovacs G; Flohr P; Berney D; Foster CS; Fletcher A; Gerald WL; Moller H; Reuter V; De Bono JS; Scardino P; Cuzick J; Cooper CS;
    Oncogene; 2008 Jan; 27(3):253-63. PubMed ID: 17637754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.